BETHESDA, Md., May 8 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq:
MITI), a biopharmaceutical company focusing on the development of novel,
proprietary antibodies for the treatment of cancer, inflammation and
autoimmune diseases, today announced its financial results for the first
quarter ended March 31, 2008.
Summary of Recent Events:
-- In April, Micromet announced the initiation of the first phase 1
clinical trial with its BiTE(R) antibody MT110. The study will explore
the safety, pharmacokinetics, pharmacodynamics and anti-tumor activity
of MT110 in patients with lung cancer and patients with
gastrointestinal cancer. MT110 targets the epithelial cell adhesion
molecule (EpCAM or CD326), which is highly expressed on colon, lung,
breast, prostate, ovarian, gastric and pancreas cancers and on cancer
stem cells of colon, breast, prostate and pancreas cancers. Cancer
stem cells are believed to cause metastases and recurrence of these
-- Also in April, Micromet presented five posters at the American
Association for Cancer Research (AACR) showing recent progress on the
company's proprietary BiTE antibody platform and new BiTE antibodies:
-- Commercial anti-cancer antibodies Herceptin(R), Erbitux(R) and
Vectibix(R) and asthma antibody Xolair(R) can be converted to highly
potent BiTE antibodies.
-- Animal data indicate feasibility of subcutaneous administration of
BiTE antibodies MT103 and MT110.
-- Animal data provided proof of concept for a BiTE antibody targeting
CD33 with potential use in the treatment of acute myelogenic
leukemia (AML), and a BiTE antibody targeting MCSP with potential
use in the treatment of melanoma.
-- Animal data suggest a therapeutic window of a BiTE antibody
targeting EpCAM in a rele
|SOURCE Micromet, Inc.|
Copyright©2008 PR Newswire.
All rights reserved